Literature DB >> 30543594

Management of epithelial ovarian cancer.

Mario M Leitao1.   

Abstract

Entities:  

Mesh:

Year:  2018        PMID: 30543594

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


× No keyword cloud information.
  4 in total

1.  Sorafenib inhibits ovarian cancer cell proliferation and mobility and induces radiosensitivity by targeting the tumor cell epithelial-mesenchymal transition.

Authors:  Chuntao Tian; Ying Liu; Lingfei Xue; Dong Zhang; Xiaotong Zhang; Jing Su; Jiaohong Chen; Xiangke Li; Liuxing Wang; Shunchang Jiao
Journal:  Open Life Sci       Date:  2022-06-15       Impact factor: 1.311

2.  MicroRNA miR-330-3p suppresses the progression of ovarian cancer by targeting RIPK4.

Authors:  Li Cai; Lu Ye; Xiaoqing Hu; Wenfeng He; Debao Zhuang; Qi Guo; Kuanyong Shu; Youkun Jie
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

3.  Plasma circN4BP2L2 is a promising novel diagnostic biomarker for epithelial ovarian cancer.

Authors:  Li Ning; Jinghe Lang; Lingying Wu
Journal:  BMC Cancer       Date:  2022-01-03       Impact factor: 4.430

4.  Overexpression of glycosyltransferase 8 domain containing 2 confers ovarian cancer to CDDP resistance by activating FGFR/PI3K signalling axis.

Authors:  Shuting Huang; Suiying Liang; Guandi Chen; Jing Chen; Keli You; Haiyan Ye; Zhigang Li; Shanyang He
Journal:  Oncogenesis       Date:  2021-07-22       Impact factor: 7.485

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.